Full Press Release Details
Reports First Quarter 2025 Financial Results and Provides Business Update
site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer
data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting
to hold conference call today at 11:00 a.m. ET
N.J., May 12, 2025 - IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated
immunotherapy, today reported financial results for the three months ended March 31, 2025 and highlighted recent business updates, including
progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer.
continues to make significant strides towards our goal of transforming the treatment landscape for women with advanced ovarian cancer.
In 2024, our Phase 1/2 OVATION 2 Study delivered groundbreaking data, demonstrating that IMNN-001 is the first immunotherapy to extend
both progression-free and overall survival in women newly diagnosed with ovarian cancer when combined with chemotherapy, and we continue
to report promising results from the trial further supporting our therapeutic approach, including new translational and safety data this
past quarter based on ongoing analyses," said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON.
look forward to building on this data and momentum, with a strong first quarter in 2025. The initiation of the first trial site for our
Phase 3 OVATION 3 pivotal study marks a critical step toward our goal of delivering a new frontline treatment for women with limited
options and urgent unmet medical needs. The acceptance of our OVATION 2 results for an oral presentation at ASCO also underscores the
scientific community's recognition of IMNN-001's potential. These milestones reflect the strength of our clinical program,
the dedication of trial investigators and patients, and our productive engagement with the FDA to finalize our Phase 3 study design.
As we advance this historic opportunity, IMUNON remains committed to bringing safe, effective therapies to women battling ovarian cancer,"
Dr. Lindborg continued.
Trial Site Initiated for Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - On
May 8, 2025, the Company announced initiation
of the first trial site for the OVATION 3 Study and is working with trial investigators to begin enrolling study participants.
Phase 3 OVATION 3 trial will assess the safety and efficacy of IMNN-001 (100 mg/m2 administered intraperitoneally weekly)
plus neoadjuvant and adjuvant chemotherapy (NACT) of paclitaxel and carboplatin compared to standard of care (SoC) NACT alone. Study
participants will be randomized 1:1 and include women with newly diagnosed advanced ovarian cancer (stage 3C or 4) who are eligible for
neoadjuvant therapy, the intent-to-treat (ITT) population, with a sub-group of women positive for homologous recombination deficiency
(HRD), including BRCA1 or BRCA2 mutations. Participants who are HRD positive will receive poly ADP-ribose polymerase (PARP) inhibitors
as part of standard maintenance therapy. The primary endpoint of the study is overall survival (OS), and secondary endpoints are surgical
response score, chemotherapy response score, clinical response and time to second-line treatment. The study will also assess several
exploratory endpoints.
Data from Phase 1/2 OVATION 2 Study to be Published in Peer-Reviewed Journal Gynecologic Oncology -
On May 6, 2025, the Company announced
that data from the Phase 1/2 OVATION 2 clinical trial evaluating intraperitoneal IMNN-001 in combination with NACT in newly diagnosed
patients with advanced epithelial ovarian cancer will be published in the peer-reviewed journal Gynecologic Oncology. The review
of full data, entitled: OVATION-2: A Randomized Phase I/II study Evaluating the Safety and Efficacy of IMNN-001 (IL-12 gene therapy)
with Neo/Adjuvant Chemotherapy in Patients Newly- Diagnosed with Advanced Epithelial Ovarian Cancer, is scheduled for publication
Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting - On April 21, 2025, IMUNON announced that
an abstract highlighting new data from the Phase 2 OVATION 2 Study of IMNN-001 to treat women with newly diagnosed advanced ovarian cancer
was accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 - June
3, 2025, in Chicago, Illinois. Details of the ASCO oral presentation are as follows:
Title: A phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT)
of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian cancer (EOC): Updated survival analysis from
Author: Premal H. Thaker, M.D., Interim Chief of Gynecologic Oncology, David & Lynn Mutch Distinguished Professor of Obstetrics
& Gynecology, Director of Gynecologic Oncology Clinical Research, Washington University School of Medicine, OVATION 2 Study Chair
Tuesday, June 3, 2025
Time: 8:00-9:30 a.m. CT
Title: Gynecologic Cancer
Data from OVATION 2 Study of
IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer -
reinforce dose-dependent mechanism
with IMNN-001 100 mg/m2 dose and continue to validate TheraPlas technology, demonstrating DNA-mediated production
of key anti-cancer immune cytokines following treatment -
On February 19, 2025, IMUNON announced
new translational data from ongoing analyses of results from the Phase 2 OVATION 2 Study of IMNN-001 for the treatment of newly diagnosed
advanced ovarian cancer. Results reinforced the dose-dependent mechanism with the IMNN-001 100 mg/m2 dose (administered intraperitoneally
weekly) and continue to validate the Company's TheraPlas technology, demonstrating DNA-mediated production of key anti-cancer immune
cytokines following treatment. The results also demonstrated a 20% increase in IL-12 levels in women treated with IMNN-001 plus SoC NACT
compared to IL-12 levels in women treated with IMNN-001 (79 mg/m2). In this analysis, increases in IL-12 levels were sampled
in the peritoneal fluid cavity, which is the primary tumor microenvironment. Little to no changes were observed in the systemic blood
stream of treated patients. In addition, the rise in IL-12 levels was accompanied by local increases in interferon-gamma (IFN- )
and tumor necrosis factor-alpha (TNF- ), key downstream anti-cancer immune cytokines. Results showed no reports of serious immune-related
adverse events including cytokine release syndrome.
DNA Vaccine Technology
Immunogenicity Data from Phase 1 Proof-of-Concept Clinical Trial of PlaCCine DNA Vaccine in COVID-19 - On February 26, 2025,
the Company announced new safety and immunogenicity data from the first Phase 1 proof-of-concept clinical trial of IMNN-101, an investigational
DNA plasmid vaccine based on the Company's proprietary PlaCCine technology platform. The Phase 1 study was conducted in 24 healthy
volunteers as a seasonal COVID-19 vaccine, targeting the SARS-CoV-2 Omicron XBB1.5 spike antigen. IMNN-101 was administered as a single
dose vaccine without a booster dose in study participants who were previously vaccinated against the Omicron XBB1.5 variant. Results
demonstrated that IMNN-101 is safe and well-tolerated with no serious adverse effects. IMNN-101 induced a persistent 2- to 4-fold increase
in serum neutralizing antibody (NAb) titers from baseline through Week 4, further increasing NAb titers between Week 2 and Week 4. The
immune response was observed against the XBB1.5 variant and many newer variants following treatment, demonstrating the IMNN-101 vaccine's
cross-reactivity. Study participants had high baseline immune characteristics presumably from prior infection and multiple previous vaccinations
against COVID-19 and ongoing infection as evidenced by the rise in viral nucleocapsid antigen during the study period. Modest increases
in T cell responses were observed in this setting of trial participants having received multiple immunizations prior to the study.
Phase 1 clinical data of IMNN-101 is consistent with strong evidence of immunogenicity and protection for the PlaCCine platform in rodents
and non-human primates, with prior preclinical results showing that protection exceeded 95% in non-human primates, which is comparable
to mRNA vaccines. The robust immunogenicity profile, expected durability of protection, comparative ease of manufacturing, and stability
at workable temperatures (up to one year at 4 C and one month at 37 C) suggest that a vaccine based on the PlaCCine technology
platform may be a potential viable alternative to available messenger RNA (mRNA) vaccines. The Company plans to seek potential partners
for further development of IMNN-101.
to Leadership Team to Support Future Clinical Programs - On February 10, 2025, the Company announced that Douglas V. Faller,
M.D., Ph.D., was appointed Chief Medical Officer of IMUNON, effective February 18, 2025. Dr. Faller has more than 30 years of industry,
academic and laboratory experience, with specialized expertise in oncology and immunology. Dr. Faller is responsible for leading the
Company's clinical strategy including advancing the IMNN-001 program for the treatment of newly diagnosed advanced ovarian cancer.
QUARTER 2025 FINANCIAL RESULTS
loss for the first quarter of 2025 was $4.1 million, or $0.28 per share, compared with a net loss of $4.9 million, or $0.52 per share,
for the first quarter of 2024. Operating expenses were $4.1 million for the first quarter of 2025, a decrease of $0.9 million or 18%
from $5.0 million for the first quarter of 2024.
and development (R&D) expenses were $2.2 million for the first quarter of 2025, a decrease of $1.1 million from $3.3 million for
the first quarter of 2024. The decrease was due primarily to lower costs associated with the OVATION 2 Study and the Phase 1 proof-of-concept
PlaCCine DNA vaccine trial, a decrease in costs associated with the development of IMNN-001 to support the OVATION 2 Study, and lower
costs associated with development of the PlaCCine DNA vaccine technology platform.
and administrative expenses were $2.0 million for the first quarter of 2025, compared with $1.7 million for the first quarter of 2024.
The increase was primarily attributable to higher employee-related expenses, partially offset by lower legal expenses.
cash used for operating activities was $2.8 million for the first quarter of 2025, compared with $5.9 million for the same period last
year. This decrease was primarily due to lower R&D expenses and higher accounts payable and accrued liability balances.
of March 31, 2025, cash and
cash equivalents were $2.9 million. The Company believes it has sufficient capital resources to fund its operations into late second
Company is hosting a conference call to review first quarter 2025 financial results and provide a business update today, May 12, 2025,
at 11:00 a.m. ET. To participate in the call, please dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll)